Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 23:15:1364503.
doi: 10.3389/fendo.2024.1364503. eCollection 2024.

Therapeutic advances in obesity management: an overview of the therapeutic interventions

Moody Al Roomy  1 , Kainat Hussain  1 , Hawraa M Behbehani  1 , Jenna Abu-Farha  1 , Rayan Al-Harris  1 , Aishwarya Mariam Ambi  1 , Mohammed Altigani Abdalla  2   3 , Fahd Al-Mulla  2 , Mohamed Abu-Farha  1   2 , Jehad Abubaker  1
Affiliations
Review

Therapeutic advances in obesity management: an overview of the therapeutic interventions

Moody Al Roomy et al. Front Endocrinol (Lausanne). .

Abstract

Obesity has become a global epidemic in the modern world, significantly impacting the global healthcare economy. Lifestyle interventions remain the primary approach to managing obesity, with medical therapy considered a secondary option, often used in conjunction with lifestyle modifications. In recent years, there has been a proliferation of newer therapeutic agents, revolutionizing the treatment landscape for obesity. Notably, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, liraglutide, and the recently approved dual GLP-1/GIP RAs agonist tirzepatide, have emerged as effective medications for managing obesity, resulting in significant weight loss. These agents not only promote weight reduction but also improve metabolic parameters, including lipid profiles, glucose levels, and central adiposity. On the other hand, bariatric surgery has demonstrated superior efficacy in achieving weight reduction and addressing overall metabolic imbalances. However, with ongoing technological advancements, there is an ongoing debate regarding whether personalized medicine, targeting specific components, will shape the future of developing novel therapeutic agents for obesity management.

Keywords: GLP-1 RAs; bariatric; obesity; tirzepatide; weight loss.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Figures

Figure 1
Figure 1
Risk factors and health consequences associated with obesity.
Figure 2
Figure 2
Mechanism of action of GLP-1 RAs and the dual GLP-1/GIP RAs .
See this image and copyright information in PMC

References

    1. Purnell JQ, Feingold K, Anawalt B, Blackman M, Boyce A, Chrousos G, et al. . Definitions, classification, and epidemiology of obesity. In: Feingold KR, Anawalt B, Blackman MR, Boyce A, Chrousos G, et al., editors. Definitions, classification, and epidemiology of obesity. Endotext. South Dartmouth MA: (2000).
    1. Weir CB, Jan A. BMI classification percentile and cut off points. In: StatPearls. Treasure Island FL: StatPearls Publishing. (2023). ineligible companies. Disclosure: Arif Jan declares no relevant financial relationships with ineligible companies. - PubMed
    1. Consultation WHOE . Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. (2004) 363:157–63. doi: 10.1016/S0140-6736(03)15268-3 - DOI - PubMed
    1. Saha J, Chouhan P, Ahmed F, Ghosh T, Mondal S, Shahid M, et al. . Overweight/obesity prevalence among under-five children and risk factors in India: A cross-sectional study using the national family health survey (2015-2016). Nutrients. (2022) 14:3621. doi: 10.3390/nu14173621 - DOI - PMC - PubMed
    1. Boutari C, Mantzoros CS. A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on. Metabolism. (2022) 133:155217. doi: 10.1016/j.metabol.2022.155217 - DOI - PMC - PubMed

Publication types

Substances